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Background: While platinum-based doublet chemotherapy is stan-
dard of care for patients presenting with metastatic non–small-cell 
lung cancer, the optimal platinum agent (cisplatin versus carbopla-
tin) is unclear. We therefore compared survival and toxicity among 
persons receiving these agents at Department of Veterans Affairs 
hospitals.
Methods: We used the Veterans Affairs Central Cancer Registry to 
identify veterans presented between 2001 and 2008 with metastatic 
non–small-cell lung cancer, then selected those receiving initial plat-
inum doublet chemotherapy. We compared survival between those 
receiving cisplatin and carboplatin using multivariable Cox propor-
tional hazards models and propensity score analyses to adjust for 
imbalances in demographics and clinical characteristics.
Results: We identified 4352 eligible persons; 4061 (93%) received 
carboplatin. Patients treated with cisplatin were younger (median age 
61 versus 63, p < 0.01) and had less comorbidities (summary comor-
bidity score > 2, 7.7% versus 12.8%, p = 0.01) and higher eGFR (87 
versus 84 mL/min/1.73 m2). Median survival was similar for persons 
receiving cisplatin and carboplatin (8.1 versus 7.5 months, p = 0.54). 
In an adjusted survival analyses, the use of cisplatin was not associ-
ated with a better survival (hazard ratio 0.98, 95% confidence inter-
val 0.84–1.14, p = 0.79). We performed subgroup analysis defined 
by histology and second agent, the hazard ratio for mortality ranged 
spanned 1 and none of these approached statistical significance (all 
p values > 0.20). Cisplatin-treated patients were more likely to have 
more hospitalization (1.7 versus 1.3, p < 0.01) and outpatient visits 
(11 versus 9.6, p < 0.01). Cisplatin-treated patient had more subse-
quent encounters for infection (41.6% versus 34.3%, p < 0.01) and 
acute kidney injury/dehydration (29.2% versus 15.5%, p < 0.01)
Conclusions: Patients receiving cisplatin and carboplatin-based dou-
blets did not have significantly different survival, but cisplatin use 
was associated with an increase morbidity and healthcare use.
Key Words: Non–small-cell lung cancer, Comparative effectiveness 
research, Outcomes research, Cisplatin, Carboplatin.
(J Thorac Oncol. 2014;9: 702–709)
Lung cancer remains the most common cause of cancer death in the United States with an estimated 228,190 new 
cases and 159,480 deaths in 2013.1 Over 80% of patients with 
lung cancer have non–small-cell lung cancer (NSCLC); most 
of these have metastatic disease at diagnosis. Although strides 
have been made in the treatment of metastatic NSCLC, the 
median survival after diagnosis remains close to a year.2
Although patients with metastatic NSCLC are not cur-
able, palliative chemotherapy improves both the quality and 
quantity of their life. A series of randomized clinical trials 
(RCTs) have established that combination chemotherapy regi-
mens including a platinum agent (cisplatin or carboplatin) and 
a second active drug are associated with an improvement in 
survival and quality of life compared with best supportive care 
alone. Thus, both European and United States guidelines rec-
ommend “platinum-doublet” regimens for first-line treatment 
of metastatic NSCLC.3–5
The preferred combination, particularly the preferred 
platinum agent, in this setting is a matter of debate. Cisplatin 
and carboplatin have different toxicity profiles; cisplatin is 
associated with a higher rate of nausea, vomiting, nephrotox-
icity, and ototoxicity, whereas carboplatin has a higher risk 
of myelosupresssion and neurotoxicity.6 Several RCTs have 
compared the outcomes of patients with metastatic NSCLC 
receiving various platinum-doublet regimens, with mixed 
results.7–9 An individual patient-data, meta-analysis found that 
cisplatin was superior in the rate of objective response (for no 
response = 0.73, 95% confidence interval [CI] 0.62–0.86, p < 
0.001) and overall survival (OS; hazard ration [HR] 0.90, 95% 
CI 0.83–0.99), but had more toxicity;10 a separate a Cochrane 
collaboration meta-analysis showed no difference in OS (HR 
1.00, 95% CI 0.51–1.97).6
In practice in the United States, most patients who 
undergo treatment for metastatic NSCLC are treated with a 
carboplatin-based regimen, in a recent analysis of Surveillance, 
Epidemiology and End Results (SEER) data only 4.5% of 
patients received cisplatin,11 in contrast in European countries 
cisplatin-based regimens, remain the standard.






Rafael Santana-Davila, MD,* Aniko Szabo, PhD,† Carlos Arce-Lara, MD,*  
Christina D. Williams, PhD,‡ Michael J. Kelley, MD,‡ and Jeff Whittle, MD§
*Division of Hematology and Oncology, Clement J. Zablocki VA Medical 
Center; †Department of Biostatistics, Medical College of Wisconsin, 
Milwaukee, WI; ‡Durham VA Medical Center, Durham, NC; and 
§Division of Primary Care, Clement J. Zablocki VA Medical Center, 
Milwaukee, WI.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Rafael Santana-Davila, MD, 9200 W. Wisconsin 
Ave, Milwaukee, Wisconsin 53226. E-mail. rsantana@mcw.edu
Original Article
703Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 5, May 2014 Treatment for Metastatic Lung Cancer
To determine whether carboplatin-based doublet use 
is associated with a shorter survival than might be achieved 
with more routine use of cisplatin-based doublets, we com-
pared outcomes of patients with newly diagnosed NSCLC 
who received cisplatin versus carboplatin-based doublet che-
motherapy regimens in the Veterans Health Administration 
(VA). We identified our patients through the VA Central 
Cancer Registry (VACCR), which data can be linked to 
other extensive VA data including the specific chemotherapy 
received, vital signs, comorbid conditions, laboratory values, 
and health care use.
MATERIALS AND METHODS
Patient Selection
Using the VACCR, we identified all consecutive 
patients diagnosed with metastatic NSCLC (See Appendix 
1, Supplemental Digital Content 1, http://links.lww.com/
JTO/A554, for the histologies included) between October 1, 
2001, and September 30, 2008. We restricted our analysis to 
patients who began chemotherapy that included a platinum 
doublet within 120 days of diagnosis and excluded patients 
who received radiation within 7 days from the start of 
chemotherapy.
Chemotherapy.
We used the VA Decision Support System pharmacy 
files to identify all cancer chemotherapy each patient received 
through the VA. We defined initial chemotherapy as all che-
motherapy agents received during the first 19 days after the 
first agent was administered. In addition to a platinum agent, 
we required that the regimen include one of docetaxel, eto-
poside, gemcitabine, irinotecan, paclitaxel, pemetrexed, or 
vinorelbine. We excluded patients who received triplet che-
motherapy, except we allowed regimens that included bevaci-
zumab in addition to a doublet. The date of radiation treatment 
was extracted from the VACCR files.
Potential confounders.
We augmented the VACCR database with data regard-
ing clinical variables and comorbid conditions drawn 
from the Medical SAS inpatient and outpatient encounter 
files (MedSAS data), the Corporate Data Warehouse, and 
Decision Support System laboratory files. We defined base-
line hemoglobin, platelet, creatinine, and albumin level as 
the mean of tests obtained within 30 days before and 7 days 
after initial treatment. We excluded biologically implausible 
values (hemoglobin > 22 or <5 g/dl; albumin > 8 g/dl), which 
made up <0.1% of observations. Plausible hemoglobin and 
albumin levels were identified in 99% (n = 4020) and 85% 
(n = 3455) of patients, respectively. Glomerular filtration 
rate was calculated using the Modification of Diet in Renal 
Disease. We defined baseline weight as the median of docu-
mented weights obtained between 3 months and 2 years pre-
ceding the day chemotherapy started. We calculated change 
in weight by subtracting the median of weights obtained dur-
ing the 15 days after the start of treatment from the baseline 
weight. Weight loss could be calculated in 85% (n = 3709) 
of our patients.
To identify comorbidities, we applied the Deyo adapta-
tion of the Charlson comorbidity index to inpatient and out-
patient encounters occurring 13 months to 1 month before 
NSCLC diagnosis.12 We calculated a summary measure of 
comorbidity, modified to exclude cancer diagnoses, using lung 
cancer specific weights as described by Klabunde et al.13,14 We 
counted the number of prior VA hospitalizations during the year 
before the start of treatment, because prior hospitalizations are 
known to predict future hospitalizations and death.15 We used 
the 2009 Area Resource File to identify area level surrogates 
for socioeconomic status (percent of adults with college educa-
tion, median household income, and rural-urban status).
Outcomes.
We obtained data regarding date of death, our primary 
outcome, from the vital status “mini” file. This provides data 
quality similar to that available from the National Death Index 
for veterans who use the VA for healthcare.16 We identified 
all VA hospitalizations and outpatient visits during the 4 
months after the start of treatment. We identified encounters 
for complications often associated with chemotherapy based 
on the presence of ICD-9 diagnosis codes associated with 
these encounters. We used previously defined coding algo-
rithms when available or devised our own based on review of 
appropriate coding documents; a detailed list of codes used to 
define complications is provided in Appendix 2 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A555). We cat-
egorized the complications as (1) infection or neutropenia; (2) 
acute kidney injury or dehydration; (3) nausea or vomiting; 
or (4) hemorrhage. We did not attempt to grade the severity 
of these complications, but note that they were significant 
enough to be coded.
Statistical Analysis
Descriptive statistics.
We calculated basic descriptive statistics, and then com-
pared the baseline characteristics of the groups receiving car-
boplatin versus cisplatin doublet (CB versus CP groups) using 
χ2 and t tests as appropriate. We prepared survival curves 
using the Kaplan-Meier method; we tested the significance 
of differences between the survival of the CB and CP groups 
using the log-rank test.
Outcome analysis.
We used two complementary approaches to adjust for 
differences in baseline characteristics: a standard Cox propor-
tional hazard model and a propensity score approach. In our 
standard Cox model, we used the stepwise selection procedure 
with a p value of 0.25 to enter the model and a p value of 0.10 
to remain. We included all variables in Table 1 as candidate 
variables and forced the inclusion of the variable defining the 
platinum agent. We tested the proportional hazards assump-
tions for each covariate individually and in the final model; all 
covariates met these assumptions. We tested for interactions 
between the primary independent variable and each covariate 
included in the final model and found none. In a sensitivity 
analyses, we repeated this analysis on the subset of patients 
with nonsquamous histology and the subset of patients 
where the second agent in the doublet was one of paclitaxel, 
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TABLE 1.  Baseline Characteristics of Person Receiving Carboplatin versus Cisplatin Doublets
Carboplatin (n = 4061) Cisplatin (n = 291) p Value
Age in years (median, interquartile range [IQR]) 63 (58–71) 61 (56–67) <0.01
Male, n (%) 3974 (97.9) 281 (96.6) 0.15
Race, n (%) 0.93
  Black 726 (17.8) 54 (18.6)
  White 3233 (79.6) 231 (79.4)
  Other 42 (1) 3 (1)
  Unknown 60 (1.5) 3 (1)
Married, n (%) 1894 (46.7) 138 (47.6) 0.78
Region, n (%) 0.09
  Midwest 482 (11.9) 47 (16.2)
  Northeast 858 (21.1) 68 (18)
  South 2025 (49.9) 135 (46.4)
  West 696 (17.1) 56 (19.2)
  Urban 3729 (91.8) 266 (91.4) 0.80
% College educated, n (%) 0.38
  Quintile 1 (lowest) 818 (20.2) 51 (17.6)
  Quintile 2 825 (20.2) 50 (17.2)
  Quintile 3 795 (20.2) 62 (21.4)
  Quintile 4 815 (19.4) 67 (23.1)
  Quintile 5 809 (20.1) 60 (20.7)
Per capita income, n (%) 0.10
  Quintile 1 (lowest) 815 (20.1) 54 (18.6)
  Quintile 2 825 (20.3) 46 (15.9)
  Quintile 3 795 (19.6) 74 (25.5)
  Quintile 4 815 (20.1) 60 (20.7)
  Quintile 5 809 (19.9) 56 (19.3)
Histologic grade, n (%) <0.01
  Well-differentiated 86 (2.1) 2 (0.7)
  Moderately differentiated 401 (9.9) 35 (12.0)
  Poorly differentiated 1190 (29.3) 83 (28.5)
  Undifferentiated 94 (2.3) 17 (5.8)
  Unknown 2290 (56.4) 154 (52.9)
Histology, n (%) 0.42
  Adenocarcinoma 1476 (36.3) 85 (29.2)
  Adenosquamous 26 (<1) 1 (<1)
  Squamous cell 1067 (26.3) 81 (27.8)
  Not otherwise specified 1481 (36.5) 124 (42.6)
  Other 11 (<1) 0
Hemoglobin (median, IQR) 12.7 (11.4–14) 12.7 (11.4–14) 0.48
Anemia, n (%) 1403 (34.9) 99 (34.7) 0.95
Platelet count (in thousands; median, IQR) 306 (238.3–393) 314.8 (242.3–404.5) 0.59
Albumin (median, IQR) 3.5 (3–3.8) 3.5 (3–3.9) 0.76
Hypoalbuminemia, n (%) 1756 (50.8) 126 (51) 0.95
eGFR (median, IQR) 84 (68.2–102.6) 87 (72.6–106.6) <0.01
Chronic kidney disease, n (%) 609 (15.3) 29 (10.2) 0.02
% Weight loss (median, IQR) 5.4 (1.5–9.9) 5.5 (1.3–10.4) 0.22
Comorbidity score (median, IQR) 1 (0–2) 1 (0–1) <0.01
Comorbidity score >2, n (%) 515 (12.8%) 22 (7.7%) 0.01
Number of hospital admission in the year preceding treatment 
(median, IQR)
1 (0–1) 1 (0–2) 0.06
* Anemia = Hgb < 12 g/dl; hypoalbuminemia = albumin < 3.5 g/dl; chronic kidney disease= eGFR < 60 ml/min/1.73 m2.
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docetaxel, gemcitabine, vinorelbine, or irinotecan, so called 
third-generation agents.
Propensity score analysis addresses the fact that choice 
of which doublet is used is driven by patient characteristics, 
some of which may also be related to outcomes. This bias is 
reduced by comparing patients who may have received cispla-
tin or carboplatin, but who were similar in their likelihood of 
receiving cisplatin. For this analysis, we first used multivari-
able logistic regression to generate a propensity score—the 
predicted likelihood of treatment with cisplatin versus carbo-
platin based on histology (squamous versus nonsquamous), 
the amount of weight loss, number of prior hospitalizations, 
hemoglobin, platelet and albumin levels, age, glomerular fil-
tration rate, and modified Charlson comorbidity index.
For the analysis of propensity scores, we followed 
the advice of Austin17 who recently established that among 
various approaches for estimating the effect of treatment on 
 time-to-event outcomes, matching and the inverse probabil-
ity of treatments weights allow for the estimation of mar-
ginal hazard ratios with minimal bias. The first uses pairs of 
individuals receiving the two treatments who are matched on 
propensity score. The second uses all cases but weights each 
observation by the inverse of the propensity for receiving the 
treatment they actually received.
For the matched-pair analysis, a greedy match approach 
was used to match patients on the logit of the propensity score 
using calipers of width equal 0.2 of the standard deviation of 
the logit of the estimated propensity score.18 We assessed the 
balance of the matched samples by comparing the standard-
ized differences of baseline covariates of the two groups. To 
compare the groups, we used a marginal Cox model carried 
out using maximum partial likelihood estimates of regression 
parameters and a robust sandwich covariance matrix.19,20
For our second analysis, inverse probability of treat-
ments weights, we first weighted each observation in the data 
set by the inverse probability of receiving the treatment they 
received, which was derived from the propensity score. We 
then fitted a Cox proportional hazards model with the dummy 
variable for the platinum agent as the only predictor variable. 
We used a robust sandwich variance estimator to account for 
the weighted nature of the sample.21
We used a significance level of 0.05 for all tests, without 
adjusting for multiple comparisons. We used the SAS statisti-
cal package V9.2 (SAS Institute, Inc., Cary, NC, http://www.
sas.com) for all analyses.
RESULTS
Patient Characteristics
We identified 20,172 individuals with metastatic NSCLC 
during the study time; 4352 patients met our inclusion crite-
ria (Fig. 1). Of these, 4061 (93%) received carboplatin. Most 
were men (97.9%), with median age of 63 years (interquar-
tile range [IQR] 57–70). The most common histologies were 
adenocarcinoma (n = 1476, 35.4%) and squamous cell carci-
noma (n = 1148, 28.3%). Patients treated with cisplatin were 
younger (median age 61 versus 63; p < 0.01) and less likely 
to have a summary comorbidity score of 2 or more (7.7% ver-
sus 12.8%, p = 0.01) in comparison with patients treated with 
carboplatin (Table 1). Cisplatin was most often combined with 
etoposide and carboplatin with paclitaxel (Table 2).
Survival outcomes.
As shown in Figure 2, the unadjusted OS curve of 
patients treated with carboplatin did not differ from that of 
patients treated with cisplatin (median OS 8.1 versus 7.5 
months, p = 0.54). This remained true in the subgroups of 
patients with nonsquamous carcinomas overall (8 versus 7.5 
months, p = 0.24) and adenocarcinomas in particular (8.1 ver-
sus 7.3 months, p = 0.96).
In our standard Cox proportional hazards model, prior 
hospitalizations, more weight loss, chronic kidney disease, 
baseline anemia, thrombocytopenia, and hypoalbuminemia 











Docetaxel 294 (7.2) 70 (24.1)
Etoposide 69 (1.7) 98 (33.7)
Gemcitabine 494 (12.2) 73 (25.1)
Irinotecan 13 (0.3) 5 (1.7)
Paclitaxel 3112 (76.6) 19 (6.5)
Pemetrexed 22 (0.5) 13 (4.5)
Vinorelbine 57 (1.4) 13 (4.5)
Bevacizumab 238 (5.9) 2 (<0.1)
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(Table 3). Survival was similar in patients treated with cispla-
tin versus carboplatin (HR 0.98, 95% CI 0.84–1.14, p = 0.79). 
Similarly, the use of cisplatin was not associated with an 
improved survival among patients with nonsquamous histol-
ogy (HR 1.19, 95% CI 0.98–1.60, p = 0.24) or patients receiv-
ing third-generation regimens (HR 1.05, 95% CI 0.857–1.26, 
p = 0.60). To exclude the possibility that patients treated with 
bevacizumab were influencing our results, we fitted another 
Cox model excluding these patients and found no advantage 
for patients treated with cisplatin (HR 0.96, 95% CI 0.82–
1.12, p = 0.58)
In our matched-pair propensity score analysis, we 
identified 201 patients treated with cisplatin who could 
be matched based on propensity scores to one patient 
receiving carboplatin. There was no difference in survival 
between the two groups (HR 0.90, 95% CI 0.74–1.09, 
p = 0.26; Fig. 3). Finally, we fitted a Cox proportional 
hazard model weighted on the inverse probability of the 
treatment that they received. This analysis also showed no 
survival advantage for those receiving cisplatin (HR 0.96, 
95% CI 0.82–1.13, p = 0.63).
We present nonmortality outcomes in Table 4. Patients 
treated with cisplatin had more hospitalizations during the 
4 months after the start of treatment (mean 1.7 versus 1.3, 
p < 0.01), but there was no difference in length of stay per hos-
pitalization (mean 10.7 versus 10.8 days, p = 0.87). Outpatient 
visits during this period were more frequent for patients 
treated with cisplatin (mean 11 versus 9.6, p < 0.01). Patients 
treated with cisplatin were also more likely to have encounters 
associated with each of the complications we examined, with 









Cox Univariate Hazard 





Cox Multivariate Hazard 




 p Value (n = 2871)
Chemotherapy agent 0.5411 0.7885
  Carboplatin 4061 8.1 — —
  Cisplatin 291 7.5 0.96 (0.85–1.09) 0.98 (0.84–1.14)
Anemia <0.0001 0.0016
  Hgb >12 gr/dl 2803 9.0 — —
  Hgb <12 gr/dl 1502 6.5 1.39 (1.31–1.49) 1.14 (1.05–1.24) .
Hypoalbuminemia <0.0001 <0.0001
  Albumin <3.5 gr/dl 1820 9.9 — —
  Albumin >3.5 gr/dl 1882 6.2 1.61 (1.51–1.72) . 1.38 (1.27–1.50)
Chronic Kidney Disease 0.1169 0.0032
  eGFR >60 ml/min 3620 8.0 — —
  eGFR <60 ml/min 638 7.8 1.07 (0.98–1.16) 1.16 (1.05–1.28)
Thrombocytopenia 0.0150 0.0703
  Platelet count >100,000 3971 8.0 — —
  Platelet count <100,000 34 3.9 1.53 (1.08–2.15) 1.451 (0.992–2.123)
Percent of Weight loss 3709 8.3 1.03 (1.03–1.04) <0.0001 1.02 (1.02–1.03) <0.0001
Number of prior hospitalizations 
in the year before diagnosis
4352 8.0 1.13 (1.10–1.17) <0.0001 1.10 (1.06–1.14) <0.0001
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DISCUSSION
In contrast to the findings in some RCTs, we found no 
survival benefit to the use of cisplatin containing combination 
chemotherapy rather than combinations based on carboplatin. 
However, as has been previously observed, cisplatin was associ-
ated with more frequent hospitalizations, outpatient visits, and 
complications. Our results support the widespread preferential 
use of carboplatin, but challenge the belief that cisplatin results 
in superior survival. Our study is an important demonstration 
of the potential utility of the rich observational VA data; our 
sample size of nearly 5000 patients dwarfs most RCTs.
Although no other large observational studies com-
paring these agents have been reported, we can compare our 
results to three meta-analyses.6,10,22 As with our study, these 
compared the two platinum agents in combination with a 
range of second agents. The first two concluded that there was 
a small benefit for cisplatin; in the individual patient-data, 
meta-analysis, cisplatin was associated with an increase in 
objective responses (for no response 0.73, 95% CI 0.62–0.86, 
p < 0.001), but no difference in survival (HR 0.93, 95% CI 
0.87–1.01, p = 0.10). However, survival was better in patients 
receiving cisplatin-based doublets in subgroups restricted to 
third-generation platinum-based regimens (HR 0.90, 95% 
CI 0.83–0.99) or nonsquamous histologies (HR 0.89, 95% 
CI 0.81–0.99).10 Ardizzoni et al.10 concluded that “cisplatin 
should remain the reference platinum agent for treatment 
of NSCLC”. Indeed, cisplatin was the platinum agent cho-
sen for several recently reported clinical trials.23–25 The third 
 meta-analysis, a Cohrane collaboration meta-analysis aggre-
gate data study that included only trials using third genera-
tion regimens did not find any survival advantage for patients 
treated with cisplatin (HR 1.00, 95% CI 0.51–1.97).6
Our study contains many limitations that we will pro-
ceed to discuss, cisplatin use was rare among our patients and 
only used in 6.7% which is consistent with what was seen 
in a SEER/Medicare analysis.11 In those who did receive it, 
close to 30% of patients treated with cisplatin in our series 
received etoposide, a regimen, that has been found to be infe-
rior to paclitaxel in the metastatic setting,26 thus there is the 
possibility that this influence the results. However, when we 
limited our analysis to patients treated with third-generation 
regimens, our results continue to show no benefit for cisplatin. 
We were not able to identify the actual dose of neither cispla-
tin nor carboplatin and relied only on whether the agent was 
used or not during the first cycle of chemotherapy. An optimal 
dose of both cisplatin and carboplatin is known to affect out-
comes,27 we are not able to establish the dose used to treat our 
patients and thus is possible that an optimal dose of cisplatin 
was not used in our patients limiting our conclusions.
We cannot determine why we could not replicate the 





Outcome* Carboplatin Cisplatin p value
Hospitalizations (mean, SD) 1.3 (1.4) 1.7 (1.7) <0.01
Length of stay in days (mean, SD 10.7 (14.4) 10.8 (15.1) 0.87
Outpatient visits (mean, SD) 9.6 (6.4) 11 (8) <0.01
At least one encounter for any of the after complications, n (%)*
  Infectious 1394 (34.3) 121 (41.6) 0.01
  Acute kidney injury/dehydration 628 (15.5) 85 (29.2) <0.01
  Nausea/vomiting 296 (7.3) 52 (17.9) <0.01
  Hemorrhage 313 (7.7) 20 (6.9) 0.60
  Any of the above 1828 (45) 169 (58.1) <0.01
*Limited to the 4 months after the initiation of chemotherapy.
SD, standard deviation.
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possibilities. First, it may be that even our healthiest sub-
groups are dissimilar to the participants in the trials demon-
strating benefit (note that several RCTs found no comparative 
benefit of cisplatin versus carboplatin).8 Although we used 
baseline albumin, weight loss, and anemia as surrogate mea-
sures of overall health, we do not have a direct measure of 
performance status. Good performance status has been an 
entry criterion for most of the trials. Second, it may be that the 
cisplatin treatment in RCTs is better than can be delivered in 
usual practice. Treatment and supportive care in RCTs follow 
a strict protocol to minimize morbidity. Such protocols may be 
infeasible in even well-resourced nontrial settings. Moreover, 
although most VA hospitals that deliver chemotherapy are 
staffed by medical school affiliated oncologists, providers 
treating patients in investigational protocols are likely to be 
particularly expert in managing complications of the study 
treatment. However, we note that our OS results are similar 
to those seen in RCTs. Finally, we acknowledge that RCTs 
are considered the standard procedure for comparative studies 
because they increase the likelihood that patient characteris-
tics, even those that are not measured, will be similar in the 
groups being compared. However, we note that the use of pro-
pensity scores allows us to balance groups based on nonclini-
cal factors that influence the choice of treatments and that we 
had consistent results with a variety of analytic approaches.
Totally apart from providing a check on the “efficacy” 
claim for cisplatin’s superiority, our study provides important 
information regarding comparative effectiveness of the two 
platinum agents in “real world” settings. We provide both cli-
nicians and patients with more precise estimates of expected 
outcomes that are needed to inform what happens outside clin-
ical trials and in a “real world” setting.28 Here, our results are 
encouraging—we observed median OS and 1- and 2-year sur-
vival rates that are almost identical to that found in the break-
through Eastern Cooperative Oncology Group 1594 study,8 
which established platinum doublet as the standard procedure 
palliative treatment. In that study, the  platinum-doublet arm 
had median OS of 8.0 month and 1- and 2-year survival rates 
of 33% and 11%, respectively, remarkably similar to the 8.1 
months, 31% and 11% seen in our cohort. Furthermore, an 
analysis of clinical trials published between 2000 and 2007 
showed survival rates similar to those seen in our cohort 
(mean 90th, 75th, 50th, 25th, and 10th percentiles of 2.4, 4.8, 
9.2, 16.3, and 25 months, respectively, versus 2.4, 4.3, 8.1, 
14.4, and 26 months seen in our cohort).29
Although RCTs are the standard procedure for com-
parisons of alternative treatments, the tightly controlled cir-
cumstances in which they are conducted makes it difficult to 
know whether similar results will be achieved in most prac-
tice settings. Observational studies such as our own comple-
ment RCTs because they study what is seen in a broader range 
of clinical settings. Most reports of the outcomes of typical 
oncology practice use the SEER-Medicare database, which is 
limited to an older population and includes only coded data 
on comorbid conditions. In contrast, the database we con-
structed by merging VACCR and other VA databases includes 
such prognostically important variables as prior hospitaliza-
tions, platelet counts and levels of hemoglobin, creatinine, 
and albumin, and percent of weight loss, in addition to coded 
diagnoses similar to those available in the SEER-Medicare 
database. Moreover, the median age of patients included in 
our study was 63 years, lower than the age of eligibility for 
Medicare (and hence the SEER-Medicare database) in the 
absence of preexisting disability.
We acknowledge that the VA setting of our study raises 
questions regarding external validity. Most obviously, our study 
sample was almost exclusively male. However, prior work has 
not suggested that the relative efficacy of the agents we stud-
ied varies by gender. In addition, prior work suggests that more 
VA patients may have smoking related lung cancer. It is hard 
to extrapolate these results to a population where a larger pro-
portion of lung cancers may be related to genetic alterations 
(i.e., EGFR mutation-positive or anaplastic lymphoma kinase 
 translocation-positive disease) rather than smoking. In addition, 
as with any study of data not gathered specifically for research, 
there are data limitations. We identified outpatient and inpatient 
complications from coded data; this should not be interpreted as a 
comprehensive analysis of side effects as it is very likely that not 
all complications are coded. Similarly, hospitalization and outpa-
tient visit data are limited to those occurring within the Veterans 
Health Administration. However, although this will reduce event 
rates, it is unlikely to bias our comparison of complication rates 
with the two agents. Likewise, although comorbidity identifica-
tion may be somewhat inaccurate when relying on coded data, 
coded comorbidity data are associated with mortality in numer-
ous studies, and the errors are unlikely to happen in a pattern that 
would bias our comparison of carboplatin and cisplatin.
The main limitation on any retrospective analysis is the 
lack of randomization, we try to overcome this with the use of 
regression models that take into account important prognostic 
information and with the use of propensity scores methodol-
ogy, with the main limitation that this resource does not cor-
rect biases from unmeasured confounders.
Finally, it is also important to note that in most of our 
analyses cisplatin-treated patients had lower hazard of death, 
even though this did not reach statistical significance, thus an 
additional possibility is that the effect of cisplatin is smaller 
than in RCTs, and there was not enough power to detect a dif-
ference in our cohort.
Despite these limitations, we believe the results of our 
study will be useful for clinicians trying to guide patients 
regarding their prognosis and reassure oncologists who 
choose to use carboplatin-based doublets because of reduced 
toxicity and similar impact on survival. In contrast to the RCT 
data suggesting that cisplatin can lead to improved survival 
in appropriate patients, we were unable to identify a subset of 
patients treated in the VHA healthcare system where this was 
the case. In contrast, we were able to confirm the significant 
increase in morbidity associated with cisplatin compared with 
carboplatin-based regimens. Thus, our study supports the use 
of carboplatin as one agent of doublet chemotherapy for all 
patients with advanced NSCLC.
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